The encyclopedia · Legal & Compliance · Legal decision · 2003–2018
Theranos raised $700M on a blood test that didn't work — its founder went to prison
Elizabeth Holmes promised hundreds of tests from a finger-prick. The 'Edison' machines didn't work; Theranos ran them on commercial analyzers and hid the truth.
Theranos · 2015-10-15
What happened
Theranos was founded in 2003 by Elizabeth Holmes, then 19, who had dropped out of Stanford. Its promise was seductive: hundreds of medical tests run from a single finger-prick of blood, using compact automated devices the company called 'Edisons.' Investors poured in more than $700 million, and at its peak in 2013-2014 Theranos was valued at about $9 billion, with Holmes hailed as the next Steve Jobs and a board stacked with statesmen.
The technology did not do what Theranos claimed. The Edison machines produced unreliable results, and the company quietly ran most tests on standard commercial analyzers bought from other manufacturers. A partnership with Walgreens put Theranos wellness centers in dozens of drugstores, where patients received results that could be wrong — regulators later found the company's Newark, California lab posed 'immediate jeopardy to patient health and safety,' including on a test that dosed the blood-thinner warfarin.
The facade cracked in October 2015, when Wall Street Journal reporter John Carreyrou published an investigation, building on the work of scientists and a young Theranos whistleblower, showing the company was using conventional machines and that its Edison results were unreliable. Theranos fought back with lawyers and denials, but regulators, investors and partners peeled away. The company voided two years of Edison results, Walgreens terminated the partnership, and Theranos dissolved in September 2018.
In 2018 the SEC charged Holmes and former president Sunny Balwani with fraud. In January 2022 a jury convicted Holmes on four counts of defrauding investors; she was sentenced to more than 11 years in prison. Balwani was convicted on all 12 counts and sentenced to nearly 13 years. Holmes's net worth, once estimated at $4.5 billion, went to zero.
Why it happened
- The core technology never worked as claimed, and the company concealed it — running tests on commercial machines while marketing a proprietary breakthrough.
- A board of prominent statesmen and a culture of secrecy and NDAs substituted for the technical due diligence investors skipped.
- Regulatory gaps let the company operate and bill before its devices were properly validated, putting patients at risk.
- The 'fake it till you make it' startup ethos was applied to medicine, where a wrong result can mean a wrong treatment.
The lesson
In a regulated, life-affecting field, the product must work before the story scales. Charisma, a famous board and NDAs are not validation — demand the data and independent verification.
Aftermath
Theranos dissolved, Holmes and Balwani went to prison, and the case became the defining cautionary tale about Silicon Valley hype meeting regulated healthcare. It sharpened scrutiny of health-tech startups, of boards that lend credibility without expertise, and of investors who fund narratives over evidence. The journalist who broke it, John Carreyrou, turned his reporting into the book Bad Blood, and 'Theranos' is now shorthand for a fraud dressed up as a breakthrough.
Sources
spotted an error? The club wants to know.
Comments · 0
Sign in to join the comments.